Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 77 for your search:
Drug:
vorinostat
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2005_010
, MK0683-014, NCT00128102
2.
Compassionate Use of Vorinostat (MK0683, SAHA) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2006_540
, MK0683-042, NCT00419367
3.
Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2008_525
, MK0683-088, NCT00773747
4.
Phase I/II Study of Vorinostat (SAHA) and Bevacizumab in Patients With Unresectable or Metastatic Renal Cell Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0570
, J0570, JHOC-00001107, NCI-6884, 6884, NCT00324870
5.
Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and over
Sponsor:
NCI
Protocol IDs:
NYWCCC-0511008257
, 6896, NCI-6896, NCT00324740
6.
Phase I/II Study of Vorinostat (SAHA) and Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NYCC-6898
, 6898, NCI-6898, NCT00392353
7.
Clinical Trial of SAHA in Patients With Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
BR03/20/05
, DSRB Reference Code: B/06/275, HSA No: CTC0600314, NCT00416130
8.
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TARZO
, NCT00503971
9.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
10.
Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NYCC1
, 07-10-374, NCT00574587
11.
Phase I/II Study of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Primary Refractory Lymphoid Malignancies or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PSOC-2302
, 6632, FHCRC-IR-6632, NCT00601718
12.
Phase I/II Study of Vorinostat, Paclitaxel, and Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Who Are Unable to Tolerate Cisplatin
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UWCC-6600
, MERCK-UWCC-6600, 6600, UWCC-UW 6600, UWCC-08-0469-H/A, NCT00662311
13.
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other
Protocol IDs:
08-045
, NCT00667615
14.
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
PSHCI 08-005
, NCT00702962
15.
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0803003591
, NCT00719875
16.
Phase I/II Study of Vorinostat in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0874
, NCCTG N0874, N0874, ABTC 0902, NCT00731731
17.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OHSU-4180
, 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
18.
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GFM VOR 2007-01
, NCT00776503
19.
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0711003269
, NCT00785798
20.
SAHA + CHOP in Untreated T-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0484
, NCT00787527
21.
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0780
, NCT00831493
22.
Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
ZMP-1
, 2008-000646-32, NCT00857324
23.
Phase I/II Study of Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
50 and over
Sponsor:
NCI
Protocol IDs:
FHCRC-2288.00
, FHCRC-2288.00, IR-6921
24.
Phase II Pilot Study of Neoadjuvant Vorinostat in Women Undergoing Surgery For Newly Diagnosed Stage I-III Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0504
, J0504, 6914, NCI-6914, NCT00262834
25.
Phase II Study of Vorinostat (SAHA) in Patients With Advanced Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
CTRC-04-10
, 6825, NCI-6825, NCT00278395
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
